Physician Withdrawal Checklist (PWC-20)
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Anxiety disorders are the most common mental illnesses in the United States. Despite having a number of medication options readily available, benzodiazepines (BZs) and antidepressants have achieved remission rates of only 35% after 8 weeks of acute treatment. In the development of new anxiolytics, particularly those that affect the gamma-aminobutyric acid system, it is essential to assess the new compound's potential to cause discontinuation symptoms after stopping the medication as part of both short- and long-term treatment. This report describes the development of the 20-item Penn Physician Withdrawal Checklist (PWC), a smaller version of the original 35-item PWC, and examines its validity, internal consistency, test-retest and interrater reliability, and factor structure. The PWC scores, assessed at the peak of withdrawal severity, were selected from 143 of our patients for an orthogonal factor analysis. Our results suggest that the Penn Physician Withdrawal Checklist is a simple and accurate method to assess anxiolytic discontinuation symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, the same definition has also been used previously in clinical studies 20,21 of patients with MDD who were selected irrespective of response to previous treatment.”
Citations
Cites
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
(2002) · PubMed · Cited by 518
The epidemiology of anxiety disorders: prevalence and societal costs.
Lépine, J. (2002) · PubMed · Cited by 396
Rickels, K. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290060008 · Cited by 384
Self-citationWithdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367 · cited 1×
“Items were added over time based either on our own clinical observation(16,17) or on reports in the literature.(18,19) In fact, most symptoms presently being used in the PWC were observed by us in the first ever reported double-blind case study of a patient who was, for 5 years, treated with 20 mg of diazepam daily(16…”
MethodLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 3×
“0001).(14) Test-retest reliability was assessed by correlating screen and baseline PWC-35 scores, assessed by the same psychiatrist, for 47 patients.”
MethodSelf-citationCarter, R. M., Wittchen, H.-U., Pfister, H., & Kessler, R. C. (2001) · Depression and Anxiety · doi:10.1002/da.1020 · Cited by 331
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. T., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.533 · Cited by 314
Long-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03340060045024 · Cited by 276
Self-citationLong-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.250.6.767 · Cited by 276
Self-citationFreeman, E. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530010065036 · Cited by 192
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175 · cited 1×
“Only select patients, namely those who continue in extended treatment, primarily with antidepressants, experience higher remission rates.(4,5) The latter patients represent, however, a rather select group of patients, namely those who either did not experience limiting adverse events or could adjust to such events, an…”
BackgroundWinokur, A. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140103012 · Cited by 156
Bruce, S. E., Vasile, R. G., Goisman, R. M., Salzman, C., Spencer, M., Machan, J. T., & Keller, M. B. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1432 · Cited by 127
Pollack, M. H., Roy-Byrne, P. P., Van Ameringen, M., Snyder, H., Brown, C., Ondrasik, J., & Rickels, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1109 · Cited by 111
Self-citationRickels, K., DeMartinis, N., García-España, F., Greenblatt, D. J., Mandos, L. A., & Rynn, M. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1973 · Cited by 110 · cited 1×
“The finally evolved PWC-35 was first reported upon in 1990(8,14) and is used by our group in BZ discontinuation studies.(20,21) The PWC-20 was developed because of the desire of researchers and clinicians to have a short, yet reliable, instrument available to detect any potential BZ-like treatment discontinuation (wit…”
MethodSelf-citationMaintenance Drug Treatment for Panic Disorder: II. Short- and Long-term Outcome After Drug Taper
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130067010 · Cited by 94
Self-citationStahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88 · cited 1×
“Despite the recommendations by experts that antidepressants should be the treatment of first choice in anxiety disorders, BZs are still frequently prescribed today according to prescription surveys.(6) They are extremely fast acting and, with the exception of sedation, have only few disturbing adverse events with acut…”
BackgroundRickels, K., Schweizer, E. E., España, F. G., Case, G. W., DeMartinis, N. A., & Greenblatt, D. J. (1999) · Psychopharmacology · doi:10.1007/s002130050798 · Cited by 83
Self-citationRemission of Generalized Anxiety Disorder: A Review of the Paroxetine Clinical Trials Database
Rickels, K., Rynn, M., Iyengar, M., & Duff, D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0107 · Cited by 69
Self-citationGepirone and Diazepam in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Rickels, K., Schweizer, E., DeMartinis, N., Mandos, L., & Mercer, C. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00006 · Cited by 64
Self-citationDifferential Efficacy of Unilateral and Bilateral ECT
FONTAINE, R., & YOUNG, T. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.8.1013-b · Cited by 62
[Unusual withdrawal symptoms after long-term administration of benzodiazepines (author's transl)].
Schöpf, J. (1981) · PubMed · Cited by 17
Mandos, L. A., Rickels, K., Cutler, N. R., Roeschen, J., Hesselink, J. M. K., & Schweizer, E. E. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199511000-00007 · Cited by 8
Self-citation
Research works printed but not linked: 1
- Schoepf, 1981, Unusual withdrawal symptoms after long-term administration of benzodiazepines., Nervenarzt, 52, 288
Cited by
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
“No evidence of withdrawal symptoms was observed during the 2 weeks after cessation of treatment with esketamine/antidepressant assessed by Physician Withdrawal Checklist-20.”
MethodInfluentialOchs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Metadata
- Authors
- Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W.
- Affiliations
- University of Pennsylvania (US)
- University of the Sciences (US)
- Corresponding author
- Rickels, Karl
- Mandos, Laura A.
- Case, George W.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-08
- Volume
- 28
- Issue
- 4
- Pages
- 447-451
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2081695582
- Cited by
- 59
- References
- 25
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 8 · 2019: 6 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 8 · 2013: 3 · 2012: 2
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-08957)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- benzodiazepine withdrawal, antidepressant discontinuation, anxiety disorders, psychometric validation, factor structure, internal consistency, inter-rater reliability, test-retest reliability
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Female, Humans, Male, Middle Aged, Physicians, Psychiatric Status Rating Scales, Psychometrics, Surveys and Questionnaires, Sensitivity and Specificity, Substance Withdrawal Syndrome, Anti-Anxiety Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.